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Acceleration of bone remodelling increases the risk of fragility fractures. The objective of the present study was to explore in elderly women
whether a vitamin D and Ca-fortified dairy product providing about 17–25 % of the recommended intakes in vitamin D, Ca and proteins
would reduce secondary hyperparathyroidism and bone remodelling in a way that may attenuate age-related bone loss in the long term.
Thirty-seven institutionalised women, aged 84·8 (SD 8·1) years, with low serum 25-hydroxyvitamin D (5·5 (SD 1·7) ng/ml) were enrolled into a
multicentre open trial to consume during 1 month two servings of soft plain cheese made of semi-skimmed milk providing daily 686 kJ
(164 kcal), 2·5mg vitamin D, 302 mg Ca and 14·2 g proteins. The primary endpoint was the change in serum carboxy terminal cross-linked
telopeptide of type I collagen (CTX), selected as a marker of bone resorption. Thirty-five subjects remained compliant. Mean serum changes
were: 25-hydroyvitamin D, þ14·5 % (P¼0·0051); parathyroid hormone (PTH), 212·3 % (P¼0·0011); CTX, 27·5 % (P¼0·01); tartrate-resistant
acid phosphatase isoform 5b (TRAP 5b), 29·9 % (P,0·0001); albumin, þ6·2 % (P,0·0001); insulin-like growth factor-I (IGF-I), þ 16·9 %
(P,0·0001); osteocalcin, þ8·3 % (P¼0·0166); amino-terminal propeptide of type 1 procollagen (P1NP), þ 19·3 % (P¼0·0031). The present
open trial suggests that fortified soft plain cheese consumed by elderly women with vitamin D insufficiency can reduce bone resorption markers
by positively influencing Ca and protein economy, as expressed by decreased PTH and increased IGF-I, respectively. The rise in the bone for-
mation marker P1NP could be explained by a protein-mediated increase in IGF-I. Thus, such a dietary intervention might uncouple, at least tran-
siently, bone resorption from bone formation and thereby attenuate age-related bone loss.
Secondary hyperparathyroidism: Fortified cheese: Calcium and protein intakes: Bone resorption and formation markers: Insulin-like
growth factor-I
In the elderly, insufficient vitamin D supply, from both skin
and dietary sources, and low Ca and protein intakes are associ-
ated with reduced bone mineral mass and increased risk of fra-
gility fracture(1 – 3). Insufficient vitamin D and Ca supply leads
to a hyper-production of parathyroid hormone (PTH), which in
turn increases bone resorption.
Low protein intake results in a reduction in the circulating
level of insulin-like growth factor-I (IGF-I) that can explain
the decline in bone formation observed under selective
protein undernutrition(3). In addition, protein deficiency can
also lead to increased bone resorption, even in the presence
of sufficient energy supply(3). In keeping with these notions,
the circulating level of IGF-I is negatively associated with
fragility fracture risk(4).
The involvement in hospitalised patients with hip fracture
of the above-mentioned pathophysiological mechanisms is
corroborated by the assessment of biochemical signs of
vitamin D insufficiency, secondary hyperparathyroidism and
protein undernutrition as expressed by low circulating levels
of prealbumin, albumin and IGF-I. Normalising the reduced
spontaneous intake of proteins by the consumption of
a casein supplement in patients with low trauma fracture
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of the proximal femur increases serum IGF-I, muscle strength
and attenuates the rapid bone loss that is observed during the
months following the hospitalisation(5).
A substantial number of hip fractures occur in subjects
living in nursing homes or institutions for the elderly(6).
In the management of primary or secondary osteoporosis
prevention of this institutionalised population, nutrition
should not be neglected, since the risk of hip fracture mark-
edly increases in subjects with a personal history of previous
fragility fracture(7).
In the present open trial, we investigated in institutionalised
elderly women the effect of a dairy supplementation, namely
in the form of a daily consumption of soft plain cheese mod-
erately fortified in vitamin D and Ca, on several biochemical
variables related to bone metabolism. Two servings of this
dairy product provided 17–25 % of the daily vitamin D, Ca
and protein recommended allowances for the elderly(8).
Materials and methods
Participants
A group of sixty-one women living in six French nursing
homes and other institutions for the elderly were screened
for eligibility according to the inclusion and exclusion criteria
preset for the trial. This initial examination took place
between 42 and 21 d before day 0 of the trial, starting on
19 January 2007.
Inclusion criteria were as follows: (1) women aged 65 years
or older living in a nursing or elderly people’s home having
given their informed consent; (2) Ca intake lower than
700 mg/d recorded by frequency questionnaire(9); (3) sun
exposure of uncovered arms limited to less than 20 min/d;
serum 25-hydroxyvitamin D (25(OH)D) $4 ng/ml in order to
avoid enrolling subjects with severe vitamin D deficiency
requiring appropriate medical management; (4) serum PTH
$46 ng/l and #150 ng/l; creatinine clearance, as calculated
according to the Cockroft formula, either normal or moderately
reduced with value $30 ml/min; no dislike for dairy products;
(5) Mini Nutritional Assessment with a score $21(10).
Exclusion criteria were: (1) consumption of food fortified in
vitamin D and/or Ca during the previous 6 months; (2) treat-
ment for osteoporosis or other bone diseases with drugs
including calcitonin, bisphosphonates, raloxifene, teriparatide
and strontium ranelate; (3) disease with poor prognosis at
short term; (4) participation in a clinical trial during the last
3 months preceding entry into the study; (5) osteoporotic frac-
ture during the 12 months preceding the study requiring some
specific therapeutic management; (6) confined to bed or taking
meals in her room. According to these inclusion and exclusion
criteria thirty-seven out of the sixty-one screened subjects
were eventually enrolled into the study.
Study design
The intervention consisted of the consumption of soft plain
cheese made of semi-skimmed milk which was fortified by
both vitamin D3 (þ1·25mg/100 g) and milk Ca thus achieving
a total Ca content of 151 mg/100 g as compared with
90–120 mg/100 g for standard fresh cheese. Two servings
were taken every day during 1 month. They provided daily:
686 kJ (164 kcal); 2·5mg vitamin D3; 302 mg Ca; 233 mg P;
14·2 g proteins. Each subject served as her own control.
The main endpoint was the change in serum carboxy term-
inal cross-linked telopeptide of type I collagen (CTX),
selected as a marker of bone resorption, after 1 month of
intervention.
The ethical committee of Lyon Sud-Est (France) approved
the protocol. This approval was ratified by the French
‘Direction Ge´ne´rale de la Sante´’.
Biochemical measurements
Ca was measured by colorimetry, Na and K by indirect poten-
tiometry with the use of specific electrodes, and creatinine by
the Jaffe reaction (Roche Diagnostics, Meylan, France).
Serum PTH, osteocalcin, amino-terminal propeptide of type
I procollagen (PINP) and CTX (cross-laps) were measured
by automated immunochemiluminescence on the Elecsys
platform (Roche Diagnostics, Meylan, France) as recently
described(11). For these four biochemical analyses the
within- and between-run CV were lower than 5 %, whatever
the concentration tested.
Bone alkaline phosphatase (BAP) was measured by
automated immunochemiluminescence on the Access II
platform (Beckman-Coulter, Chaska, MN, USA). Bone alkaline
phosphatase within-run CV was 6·7 % at the mean concentration
of 13·2mg/l and below 5 % at concentrations above 25mg/l.
Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b), a
surrogate marker of osteoclast number, was determined by
immunoassay using a monoclonal antibody raised against
TRAP 5b purified from human osteoclasts, and recombinant
human TRAP as a standard (Bone TRAPw Enzyme Assay
kit; SBA Sciences, Turku, Finland). Intra- and inter-assay
CV were lower than 4·8 and 5·2 %, respectively.
The serum level of 25(OH)D was measured by RIA
(DiaSorin, Stillwater, MN, USA). Serum IGF-I was measured
by an immunoradiometric assay (IGF-I RIA-CT; Schering-Cis
Bio, Gif sur Yvette, France) based on the use of two mono-
clonal antibodies directed toward different IGF-I epitopes as
previously described(11).
Statistical analysis
The statistical power was estimated from the expected change
in serum CTX. A reduction in serum CTX by 15 % after
1 month of intervention was assumed. To achieve a power
of 80 % and a two-sided a of 0·05, such a 15 % difference
in serum CTX required a sample of fourteen subjects, taking
into account a measured intra-individual CV of 10 %.
Thirty-seven subjects were eventually enrolled in order to
secure greater power to the study.
The results were expressed as mean values and standard
deviations. Paired Student’s t tests were employed to assess
differences between the values measured before and after
1 month of intervention. For osteocalcin a Wilcoxon
rank-sum test was applied, because of its skewed distribution.
P values #0·05 were considered as statistically signi-
ficant. Statistical analysis was made using SAS software
(version 8.02; SAS Institute, Inc., Cary, NC, USA).
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Results
The baseline characteristics of the thirty-seven subjects
were: age 84·8 (SD 8·1) years with standing height of 155·7
(SD 6·4) cm, body weight of 67·5 (SD 12·8) kg and computed BMI
of 27·9 (SD 5) kg/m2. Ca intake amounted to 549 (SD 134) mg/d.
Sixteen (43·2 %) out of the thirty-seven women had experienced
a non-vertebral fracture after the menopause at the level of
either the proximal femur (n 10), wrist and forearm (n 4) or
ribs (n 2). At baseline serum creatinine was 80·9 (SD 19·9;
normal range 44–80) mmol/l. The calculated renal clearance
was 51 (SD 21) ml/min.
The duration of the dietary intervention was 29·8 (SD 2·2,
range 20–32) d. Four subjects dropped out of the study for
the following reasons: viral gastroenteritis, nausea and vomit-
ing, informed consent withdrawal, hospitalisation for fracture
of both tibia and fibula, after 2, 3, 20 and 28 d of product con-
sumption, respectively. Two subjects who were compliant
during 20 and 28 d with blood and urine collected by the
end of the intervention period were kept in the statistical com-
putation. Results of thirty-five subjects were analysed at base-
line and by the end of the intervention. The average number of
servings consumed per d was 2·0 (SD 0·1) in the thirty-five
subjects.
The absolute values of the serum variables before and by
the end of the intervention are presented in Table 1. The
serum level of 25(OH)D was markedly inferior to the
threshold value (30 ng/ml) below which vitamin D insuffi-
ciency is defined(12). It was associated with an elevation in
serum PTH above the upper limit of the normal range.
By the end of the intervention, the mean values of 25(OH)D
and PTH were slightly but significantly increased and
decreased, respectively. CTX, the marker of bone resorption
that was selected as the primary endpoint, was significantly
decreased (Table 1). Whereas CTX is considered to reflect
osteoclast function, the other serum marker of bone resorption
TRAP 5b, a circulating enzyme that would reflect higher
osteoclast number(13), was also reduced. In contrast, the
serum level of two markers of bone formation, namely osteo-
calcin and amino-terminal propeptide of type I procollagen,
were significantly increased, while bone alkaline phosphatase
remained unchanged. Associated with a positive change in
serum albumin was a significant elevation in IGF-I (Table 1).
The percentage changes from baseline of these variables are
depicted in Fig. 1.
Discussion
The present study suggests that in institutionalised elderly
women with low levels of 25(OH)D, it is possible to signifi-
cantly reduce serum markers of bone resorption by the daily
consumption of a dairy product that provides 17–25 % of
the recommended allowance for vitamin D (10–15mg), and
25 % for both Ca (1200 mg) and proteins (1·0 g/kg body
weight)(8).
Following the daily consumption of two servings of soft
plain cheese during 1 month, the vitamin D supplement of
2·5mg/d led to a small, although significant, increment in
serum 25(OH)D. Such a result could be expected since the
amount of vitamin D added to the tested dairy product was
quite modest. The estimate of the minimum level of serum
25(OH)D that is optimal for fracture prevention varies
between 20 and 32 ng/ml (50 to 80 nmol/l) according to the
opinion of several clinical investigators(12). Despite quite sat-
isfactory adherence to and persistence of the consumption of
the soft plain cheese, mean 25(OH)D remained noticeably
below (6·3 ng/ml) this minimum level. Therefore, it appears
unlikely that the very mild augmentation in 25(OH)D might
explain the significant reduction of serum PTH by 12·3 % as
well as the decrement of the two bone resorption markers
CTX and TRAP 5b, by 27·5 and 29·9 %, respectively.
Other mechanisms were presumably involved. The increased
consumption of both Ca and proteins may well have played
a major role in the inhibition of PTH and consecutive lowering
Table 1. Serum biochemical variables before and after soft plain cheese consumption in thirty-five institutionalised women
(Mean values and standard deviations)
Before After
Reference values Mean SD Mean SD Difference P *
Ca (mmol/l) 2·20–2·60 2·29 0·09 2·27 0·11 20·02 NS
Phosphate (mmol/l) 0·85–1·40 1·18 0·12 1·21 0·16 þ0·03 NS
Albumin (g/l) 35–50 33·9 2·7 36·0 2·6 þ2·1† ,0·0001
Prealbumin (g/l) 0·10–0·40 0·241 0·044 0·237 0·048 20·004 NS
25(OH)D (ng/ml) 30–80 5·5 1·7 6·3 1·7 þ0·8† 0·0051
PTH (ng/l) 10–46‡ 74·9 22·6 65·7 23·7 29·2† 0·0011
CTX (pmol/l) 700–3000‡ 4979 2462 4607 2147 2372† 0·01
TRAP 5b (U/l) 1·03–4·15§ 4·85 1·46 4·37 1·34 20·47† ,0·0001
Osteocalcin (ng/ml) 13–32‡ 32·6 14·6 35·3 17·5 þ2·7† 0·0166
BAP (mg/ml) 4–15‡ 16·4 10·1 16·5 13·8 þ0·1† NS
PINP (ng/ml) 19–50‡ 82·4 46·5 98·3 76·1 þ15·9† 0·0031
IGF-I (ng/ml) 68–247 131·7 54·6 154·0 49·0 þ22·2† ,0·0001
25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; CTX, carboxy terminal cross-linked telopeptide of type I collagen; TRAP 5b, tartrate-resistant acid phosphatase iso-
form 5b; BAP, bone alkaline phosphatase; PINP, amino-terminal propeptide of type I procollagen; IGF-I; insulin-like growth factor-I.
* Level of statistical significance by paired t test with the exception of osteocalcin of which the skewed distribution required the use of the Wilcoxon rank-sum test.
† Biochemical tests were not carried out in one patient who experienced lower-limb fracture at day 28 (for further details, see the Results section).
‡ Reference range established in healthy premenopausal women aged 35–48 years.
§ Reference range established in healthy premenopausal women aged 22–54 years.
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of the two markers of bone resorption. Besides the increased
amount of ingested Ca, its intestinal absorption might have
been enhanced by the additional protein supply(14).
The need to use various ways of reducing the age-related
acceleration of bone loss is of prime importance in order to
reduce the burden of osteoporosis in the future. In patients
with established osteoporosis, treatment using efficacious
pharmaceutical agents is undoubtedly the best approach for
reducing the risk of further fractures. However, even in
these subjects nutrition should not be neglected, since
inadequate intake of Ca, vitamin D and proteins may limit
the efficacy of anti-osteoporotic drugs(2,15).
In the present study, more than 40 % of the enrolled women
had already experienced fractures from the time of meno-
pause. Nearly 90 % of the recorded fractures were localised
at the proximal femur and forearm levels, the two main skel-
etal sites where non-vertebral osteoporotic fractures do occur.
This information indicates that a large proportion of our
cohort was at increased risk of experiencing new fragility
fractures(7), underscoring the importance of osteoporosis
prevention, whether primary or secondary, in institutionalised
elderly women.
The conclusions that can be drawn from the present open
trial are obviously limited, since its design did not allow
one to compare a period with and without the consumption
of the tested fortified soft plain cheese. Nonetheless, the
results obtained in the six participating nursing homes were
coherent in terms of subject compliance to the tested food
as well as of the changes observed in PTH, bone resorption
and formation markers, and IGF-I. The biochemical
variations measured from baseline to intervention end
are also in agreement with previous results obtained in
well-controlled experimental and clinical investigations as
designed to test the effects of whole dairy products, or
more selectively of either Ca or milk proteins(15). Therefore,
it appears unlikely that the statistically significant and bio-
logically coherent changes we recorded in the present open
trial conducted in elderly women would be unrelated to the
specific dietary intervention.
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